Explore a selection of our essential drug information below, or:
Identification
- Summary
Sodium lauryl sulfoacetate is a laxative indicated in the treatment of constipation and bowel preparation for rectal endoscopy.
- Generic Name
- Sodium lauryl sulfoacetate
- DrugBank Accession Number
- DB13157
- Background
Sodium lauryl sulfoacetate is a wetting agent and surfactant used in enema-type laxative products.
- Type
- Small Molecule
- Groups
- Approved, Experimental
- Structure
Structure for Sodium lauryl sulfoacetate (DB13157)
- Weight
- Average: 330.41
Monoisotopic: 330.14768942 - Chemical Formula
- C14H27NaO5S
- Synonyms
- Lathanol
- Lathanol LAL
- Sulfoacetic acid dodecyl ester S-sodium salt
Pharmacology
- Indication
Sodium lauryl sulfoacetate is not an active pharmacological ingredient in pharmaceutical preparations and so has no official indication.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Treatment of Constipation ••• ••• - Associated Therapies
- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Sodium lauryl sulfoacetate acts as a wetting agent and surfactant in pharmaceutical preparations 1. It is currently used in enema-type laxatives.
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Microlax - Microklistier Sodium lauryl sulfoacetate (45 mg) + Sodium citrate (450 mg) + Sorbitol (3125 mg) Enema Rectal Johnson & Johnson 1962-06-20 Not applicable Austria 
Microlax Micro Enema Sodium lauryl sulfoacetate (9 mg / mL) + Sodium citrate (90 mg / mL) + Sorbitol (625 mg / mL) Enema; Liquid Rectal Mcneil Consumer Healthcare Division Of Johnson & Johnson Inc 1995-12-31 2020-08-06 Canada 
Microlax Micro-enema Sodium lauryl sulfoacetate (9 g / 1 L) + Sodium citrate (90 g / 1 L) + Sorbitol (625 g / 1 L) Liquid Rectal Kabi Pharmacia Canada Inc. 1993-12-31 1996-09-10 Canada STITILAX Sodium lauryl sulfoacetate (0.04515 g/5ml) + Sodium citrate (0.45 g/5ml) + Sorbitol (4.465 g/5ml) Enema Rectal Carlo Erba O.T.C. S.R.L. 2018-05-01 Not applicable Italy 
STITILAX Sodium lauryl sulfoacetate (0.04515 g/5ml) + Sodium citrate (0.45 g/5ml) + Sorbitol (4.465 g/5ml) Enema Rectal Carlo Erba O.T.C. S.R.L. 2018-05-01 Not applicable Italy
Categories
- ATC Codes
- A06AG11 — Sodium lauryl sulfoacetate, incl. combinations
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as organosulfonic acids. These are compounds containing the sulfonic acid group, which has the general structure RS(=O)2OH (R is not a hydrogen atom).
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Organic sulfonic acids and derivatives
- Sub Class
- Organosulfonic acids and derivatives
- Direct Parent
- Organosulfonic acids
- Alternative Parents
- Sulfonyls / Alkanesulfonic acids / Carboxylic acid esters / Monocarboxylic acids and derivatives / Organic sodium salts / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds / Organic cations
- Substituents
- Aliphatic acyclic compound / Alkanesulfonic acid / Carbonyl group / Carboxylic acid derivative / Carboxylic acid ester / Hydrocarbon derivative / Monocarboxylic acid or derivatives / Organic alkali metal salt / Organic cation / Organic oxide
- Molecular Framework
- Aliphatic acyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- D0Y70F2B9J
- CAS number
- 1847-58-1
- InChI Key
- UAJTZZNRJCKXJN-UHFFFAOYSA-M
- InChI
- InChI=1S/C14H28O5S.Na/c1-2-3-4-5-6-7-8-9-10-11-12-19-14(15)13-20(16,17)18;/h2-13H2,1H3,(H,16,17,18);/q;+1/p-1
- IUPAC Name
- sodium 2-(dodecyloxy)-2-oxoethane-1-sulfonate
- SMILES
- [Na+].CCCCCCCCCCCCOC(=O)CS([O-])(=O)=O
References
- General References
- US Patent 3211614 [Link]
- External Links
- PubChem Compound
- 23668827
- PubChem Substance
- 347829267
- ChemSpider
- 15024
- 314832
- Wikipedia
- Sodium_citrate/sodium_lauryl_sulfoacetate/glycerol
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Enema Rectal Enema; liquid Rectal Liquid Rectal Emulsion Rectal - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.00576 mg/mL ALOGPS logP 4.49 ALOGPS logP 4 Chemaxon logS -4.8 ALOGPS pKa (Strongest Acidic) -1.1 Chemaxon pKa (Strongest Basic) -7.3 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 4 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 83.5 Å2 Chemaxon Rotatable Bond Count 14 Chemaxon Refractivity 77.32 m3·mol-1 Chemaxon Polarizability 34.95 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS splash10-0006-4910000000-a5b25e7fc7b3d48b7aff - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 192.9658026 predictedDarkChem Lite v0.1.0 [M-H]- 165.48494 predictedDeepCCS 1.0 (2019) [M+H]+ 193.5422026 predictedDarkChem Lite v0.1.0 [M+H]+ 168.93732 predictedDeepCCS 1.0 (2019) [M+Na]+ 193.0029026 predictedDarkChem Lite v0.1.0 [M+Na]+ 176.68436 predictedDeepCCS 1.0 (2019)
Drug created at December 05, 2016 03:16 / Updated at June 08, 2021 11:32